ethyl 2-amino-4-(3-chlorobenzoyl)thiazole-5-carboxylate | 899354-40-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: ethyl 2-amino-4-(3-chlorobenzoyl)thiazole-5-carboxylate
• 英文别名: 2-amino-4-(3-chloro-phenyl)-thiazole-5-carboxylic acid ethyl ester；Ethyl 2-amino-4-(3-chloro)phenyl thiazole-5-carboxylate；ethyl 2-amino-4-(3-chlorophenyl)-1,3-thiazole-5-carboxylate
• CAS: 899354-40-6
• 化学式: C₁₂H₁₁ClN₂O₂S
• 分子量: 282.751
• InChiKey: SPZCHSYCFKKIBY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  93.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 2-amino-4-(3-chlorobenzoyl)thiazole-5-carboxylate 在 palladium 10% on activated carbon 盐酸 、 三氟二甲基硫醚络合物 、 水 、 氢气 、 potassium carbonate 、 氯化铵 、 caesium carbonate 、 溶剂黄146 、 苯基锂 、 N,N-二异丙基乙胺 、 lithium hydroxide 、 锌 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， -78.0~80.0 ℃ 、344.75 kPa 条件下， 反应 11.5h， 生成 4-(3-chloro-phenyl)-2-[6-(4-morpholin-4-yl-butyl)-benzoimidazol-1-yl]-thiazole-5-carboxylic acid
  参考文献：
  名称：

  Thiazolyl-Benzimidazoles

  摘要：

  这项发明涉及到式（1）的化合物及其药用可接受盐，其制备方法和使用方法。

  公开号：

  US20100160308A1
• 作为产物：
  描述：

  (3-氯苯甲酰)乙酸乙酯 在 N-溴代丁二酰亚胺(NBS) 、 三氟甲磺酸三甲基硅酯 作用下， 以 乙醇 、 乙腈 为溶剂， 生成 ethyl 2-amino-4-(3-chlorobenzoyl)thiazole-5-carboxylate
  参考文献：
  名称：

  Synthesis and biological evaluation of novel thiazole- VX-809 hybrid derivatives as F508del correctors by QSAR-based filtering tools

  摘要：

  The most common CF mutation, F508del, impairs the processing and gating of CFTR protein. This deletion results in the improper folding of the protein and its degradation before it reaches the plasma membrane of epithelial cells. Present correctors, like VX809 only induce a partial rescue of the mutant protein. Our previous studies reported a class of compounds, called aminoarylthiazoles (AATs), featuring an interesting activity as correctors. Some of them show additive effect with VX809 indicating a different mechanism of action. In an attempt to construct more interesting molecules, it was thought to generate chemically hybrid compounds, blending a portion of VX809 merged to the thiazole scaffold. This approach was guided by the development of QSAR analyses, which were performed based on the F508del correctors so far disclosed in the literature. This strategy was aimed at exploring the key requirements turning in the corrector ability of the collected derivatives and allowed us to derive a predictive model guiding for the synthesis of novel hybrids as promising correctors. The new molecules were tested in functional and biochemical assays on bronchial CFBE41o-cells expressing F508del-CFTR showing a promising corrector activity. (C) 2017 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2017.12.030

文献信息

• Thiazolyl-benzimidazoles
  申请人：Hoffmann-La Roche Inc.

  公开号：US08044213B2

  公开（公告）日：2011-10-25

  The invention is directed to compounds of formula (1) and pharmaceutically acceptable salts thereof, methods for the preparation thereof, and methods of use thereof.

  本发明涉及公式（1）的化合物及其药学上可接受的盐，其制备方法以及使用方法。
• THIAZOLYL-BENZIMIDAZOLES
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2379543A2

  公开（公告）日：2011-10-26
• US8044213B2
  申请人：——

  公开号：US8044213B2

  公开（公告）日：2011-10-25
• [EN] THIAZOLYL-BENZIMIDAZOLES<br/>[FR] THIAZOLYL-BENZIMIDAZOLES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2010121675A2

  公开（公告）日：2010-10-28

  The invention is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, methods for the preparation of said compounds, as well as their use as medicaments, in particular for the treatment of cancer.